Global Biopharmaceutical CDMO Service 麻豆原创 Research Report 2024

Publication ID:

PB512240227

Publication Date:

December 27, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Biopharmaceutical CDMO Service was valued at US$ 24220 million in the year 2023 and is projected to reach a revised size of US$ 59060 million by 2030, growing at a CAGR of 13.1% during the forecast period.
Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.
Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.
Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.
Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.
To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.
The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.
Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.
CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.
This report aims to provide a comprehensive presentation of the global market for Biopharmaceutical CDMO Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biopharmaceutical CDMO Service.
The Biopharmaceutical CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biopharmaceutical CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biopharmaceutical CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Segment by Type
Cell and Gene Therapies
Antibodies
Vaccines
Other
Segment by Application
SMBs
Large Companies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biopharmaceutical CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Biopharmaceutical CDMO Service 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cell and Gene Therapies
1.2.3 Antibodies
1.2.4 Vaccines
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Biopharmaceutical CDMO Service 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biopharmaceutical CDMO Service 麻豆原创 Perspective (2019-2030)
2.2 Global Biopharmaceutical CDMO Service Growth Trends by Region
2.2.1 Global Biopharmaceutical CDMO Service 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biopharmaceutical CDMO Service Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Biopharmaceutical CDMO Service Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Biopharmaceutical CDMO Service 麻豆原创 Dynamics
2.3.1 Biopharmaceutical CDMO Service Industry Trends
2.3.2 Biopharmaceutical CDMO Service 麻豆原创 Drivers
2.3.3 Biopharmaceutical CDMO Service 麻豆原创 Challenges
2.3.4 Biopharmaceutical CDMO Service 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biopharmaceutical CDMO Service Players by Revenue
3.1.1 Global Top Biopharmaceutical CDMO Service Players by Revenue (2019-2024)
3.1.2 Global Biopharmaceutical CDMO Service Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Biopharmaceutical CDMO Service 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biopharmaceutical CDMO Service Revenue
3.4 Global Biopharmaceutical CDMO Service 麻豆原创 Concentration Ratio
3.4.1 Global Biopharmaceutical CDMO Service 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical CDMO Service Revenue in 2023
3.5 Global Key Players of Biopharmaceutical CDMO Service Head office and Area Served
3.6 Global Key Players of Biopharmaceutical CDMO Service, Product and Application
3.7 Global Key Players of Biopharmaceutical CDMO Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biopharmaceutical CDMO Service Breakdown Data by Type
4.1 Global Biopharmaceutical CDMO Service Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Biopharmaceutical CDMO Service Forecasted 麻豆原创 Size by Type (2025-2030)
5 Biopharmaceutical CDMO Service Breakdown Data by Application
5.1 Global Biopharmaceutical CDMO Service Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Biopharmaceutical CDMO Service Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Biopharmaceutical CDMO Service 麻豆原创 Size (2019-2030)
6.2 North America Biopharmaceutical CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2019-2024)
6.4 North America Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biopharmaceutical CDMO Service 麻豆原创 Size (2019-2030)
7.2 Europe Biopharmaceutical CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2019-2024)
7.4 Europe Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biopharmaceutical CDMO Service 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Biopharmaceutical CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biopharmaceutical CDMO Service 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Biopharmaceutical CDMO Service 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biopharmaceutical CDMO Service 麻豆原创 Size (2019-2030)
9.2 Latin America Biopharmaceutical CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biopharmaceutical CDMO Service 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Biopharmaceutical CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Biopharmaceutical CDMO Service 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Biopharmaceutical CDMO Service Introduction
11.1.4 Lonza Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Biopharmaceutical CDMO Service Introduction
11.2.4 Catalent Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.2.5 Catalent Recent Development
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Details
11.3.2 Samsung Biologics Business Overview
11.3.3 Samsung Biologics Biopharmaceutical CDMO Service Introduction
11.3.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.3.5 Samsung Biologics Recent Development
11.4 FUJIFILM Diosynth Biotechnologies
11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Introduction
11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Service Introduction
11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.5.5 Boehringer Ingelheim Recent Development
11.6 WuXi Biologics
11.6.1 WuXi Biologics Company Details
11.6.2 WuXi Biologics Business Overview
11.6.3 WuXi Biologics Biopharmaceutical CDMO Service Introduction
11.6.4 WuXi Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.6.5 WuXi Biologics Recent Development
11.7 Recipharm
11.7.1 Recipharm Company Details
11.7.2 Recipharm Business Overview
11.7.3 Recipharm Biopharmaceutical CDMO Service Introduction
11.7.4 Recipharm Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.7.5 Recipharm Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Biopharmaceutical CDMO Service Introduction
11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 AGC Biologics
11.9.1 AGC Biologics Company Details
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Biopharmaceutical CDMO Service Introduction
11.9.4 AGC Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.9.5 AGC Biologics Recent Development
11.10 Rentschler Biopharma
11.10.1 Rentschler Biopharma Company Details
11.10.2 Rentschler Biopharma Business Overview
11.10.3 Rentschler Biopharma Biopharmaceutical CDMO Service Introduction
11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.10.5 Rentschler Biopharma Recent Development
11.11 KBI Biopharma
11.11.1 KBI Biopharma Company Details
11.11.2 KBI Biopharma Business Overview
11.11.3 KBI Biopharma Biopharmaceutical CDMO Service Introduction
11.11.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.11.5 KBI Biopharma Recent Development
11.12 Siegfried
11.12.1 Siegfried Company Details
11.12.2 Siegfried Business Overview
11.12.3 Siegfried Biopharmaceutical CDMO Service Introduction
11.12.4 Siegfried Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.12.5 Siegfried Recent Development
11.13 Aenova Group
11.13.1 Aenova Group Company Details
11.13.2 Aenova Group Business Overview
11.13.3 Aenova Group Biopharmaceutical CDMO Service Introduction
11.13.4 Aenova Group Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.13.5 Aenova Group Recent Development
11.14 GenScript
11.14.1 GenScript Company Details
11.14.2 GenScript Business Overview
11.14.3 GenScript Biopharmaceutical CDMO Service Introduction
11.14.4 GenScript Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.14.5 GenScript Recent Development
11.15 ProBioGen
11.15.1 ProBioGen Company Details
11.15.2 ProBioGen Business Overview
11.15.3 ProBioGen Biopharmaceutical CDMO Service Introduction
11.15.4 ProBioGen Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.15.5 ProBioGen Recent Development
11.16 Northway Biotech
11.16.1 Northway Biotech Company Details
11.16.2 Northway Biotech Business Overview
11.16.3 Northway Biotech Biopharmaceutical CDMO Service Introduction
11.16.4 Northway Biotech Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.16.5 Northway Biotech Recent Development
11.17 3P Biopharmaceuticals
11.17.1 3P Biopharmaceuticals Company Details
11.17.2 3P Biopharmaceuticals Business Overview
11.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Service Introduction
11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Service Business (2019-2024)
11.17.5 3P Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.